Salmeterol plus theophylline combination therapy in the treatment of COPD

Chest

Volumn 119, Issue 6, 2001, Pages 1661-1670

  Zu Wallack, Richard L ^a   Mahler, Donald A ^b   Reilly, Donna ^c   Church, Nina ^c   Emmett, Amanda ^c   Rickard, Kathleen ^c   Knobil, Katharine ^c  

^a SAINT FRANCIS HOSPITAL AND MEDICAL CENTER   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Chronic bronchitis; Combination therapy; COPD; Dyspnea; Emphysema; Exacerbations; FEV1; Quality of life; Salmeterol; Theophylline

Indexed keywords

SALBUTAMOL; SALMETEROL; THEOPHYLLINE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DYSPNEA; FEMALE; HUMAN; LUNG FUNCTION; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MONITORING; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SATISFACTION; SYMPTOM;

EID: 0034892541     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.119.6.1661     Document Type: Article

References (53)

1. Optimal assessment and management of chronic obstructive pulmonary disease (COPD): The European Respiratory Society Task Force
2. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease
3. Effects of theophylline on diaphragmatic strength and fatigue in patients with chronic obstructive pulmonary disease
4. Effect of theophylline on diaphragmatic and other skeletal muscle function
5. Effect of theophylline on diaphragmatic muscle function
6. Sustained-release theophylline reduces dyspnea in non reversible obstructive airways disease
7. Effects of aminophylline upon the exercise performance of patients with stable chronic airflow limitation
8. A randomized controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease
9. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD)
10. Efficacy, tolerability, and effects on quality of life of inhaled salmeterol and oral theophylline in patients with mild-to-moderate chronic obstructive pulmonary disease
11. Quality of life changes in COPD patients treated with salmeterol
12. Efficacy of salmeterol xinafoate in the treatment of COPD
13. A comparison of the bronchodilating effects of salmeterol, salbutamol and ipratropium bromide in patients with chronic obstructive pulmonary disease
14. A combination with clinical recommended dosages of salmeterol and ipratropium is not more effective than salmeterol alone in patients with chronic obstructive pulmonary disease
15. Comparison of the effects of salmeterol and ipratropium bromide on exercise performance and breathlessness in patients with stable chronic obstructive pulmonary disease
16. Salmeterol reduces dyspnea and improves lung function in patients with COPD
17. Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: A single center randomised, double blind, placebo controlled crossover study
18. Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease
19. Reference spirometric values using techniques and equipment that meet ATS recommendations
20. The measurement of dyspnea: Contents, interobserver agreement, and physiologic correlates of two new clinical indexes
21. A measure of quality of life for clinical trials in chronic lung disease
22. Reliability and validity of the chronic respiratory questionnaire (CRQ)
23. A comparison of inhaled ipratropium, oral theophylline plus inhaled β-agonist, and the combination of all three in patients with COPD
24. Theophylline as a bronchodilator in COPD and its combination with inhaled β-adrenergic drugs
25. The efficacy of orally administered theophylline, inhaled salbutamol, and a combination of the two as chronic therapy in the management of chronic bronchitis with reversible air-flow obstruction
26. 2-adrenostimulants in asthmatics
27. Value of theophylline treatment in patients handicapped by chronic obstructive lung disease
28. 2-agonist in the treatment of stable COPD?
29. The additive effect of theophylline on a high-dose combination of inhaled salbutamol and ipratropium bromide in stable COPD
30. Effects of theophylline and ipratropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease
31. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone
32. 2 agonists in patients with chronic obstructive pulmonary disease
33. Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease
34. The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD
35. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium
36. Mechanisms in COPD: Differences from asthma
37. Theophylline: Potential anti-inflammatory effects in nocturnal asthma
38. The effects of theophylline on mucosal inflammation in asthma airways: Biopsy results
39. Theophylline inhibits the late asthmatic response to nighttime antigen challenge in patients with mild atopic asthma
40. Intranasal salmeterol inhibits allergen-induced vascular permeability but not mast cell activation or cellular infiltration
41. Increased cAMP levels in stimulated neutrophils inhibit their adhesion to human bronchial epithelial cells
42. 2-agonists: Inhibition of TNF-α release from human mast cells
43. Salmeterol: A potent and long-acting inhibitor of inflammatory mediator release from human lung
44. Formoterol on airway smooth muscle and human lung mast cells: A comparison with salbutamol and salmeterol
45. Anti-inflammatory, membrane-stabilizing interactions of salmeterol with human neutrophils in vitro
46. The effects of salmeterol and salbutamol on ciliary beat frequency in cultured human bronchial epithelial cells, in vitro
47. Effect of salmeterol on Pseudomonas aeruginosa infection of respiratory mucosa
48. Effect of salmeterol on Haemophilus influenzae infection of respiratory mucosa in vitro
49. Assessment of bronchodilator efficacy in symptomatic COPD: Is spirometry useful?
50. How should health-related quality of life be assessed in patients with COPD?
51. Impact of dyspnea and physiologic function on general health status in patients with chronic obstructive pulmonary disease
52. Early reversibility to salbutamol does not always predict bronchodilation after salmeterol in stable chronic obstructive pulmonary disease
53. Responses of large doses of salbutamol and theophylline in patients with chronic obstructive pulmonary disease